On October 11, 2021 Redx Pharma (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, reported it is hosting a Virtual R&D Day later today between 1:00pm-2:30pm BST (8:00am-9:30am EDT) (Press release, Redx Pharma, OCT 11, 2021, View Source [SID1234591060]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The R&D Day will feature updates from the Company’s leadership team and presentations from leading experts in the fields of colorectal cancer and fibrosis. Focus will be on Redx’s wholly owned lead product RXC004, a selective Porcupine inhibitor. Redx plans to commence a global Phase 2 monotherapy programme with RXC004 in three cancer types with Wnt-ligand dependent tumours: microsatellite stable metastatic colorectal cancer, pancreatic cancer and biliary tract cancer. RXC004 is also currently being investigated in a Phase 1 study in combination with the anti-PD-1antibody nivolumab.
There will also be an update on the wholly owned selective ROCK2 inhibitor RXC007, being developed for idiopathic pulmonary fibrosis. Encouraging new clinical data from the ongoing RXC007 Phase 1 study* in healthy volunteers shows:
• An excellent safety and pharmacokinetic profile
• No adverse events following single dose of 2-40 milligram
• Pharmacokinetics as predicted from preclinical data
• Essentially linear exposure for 2-40 milligram
• Biologically relevant exposures achieved at higher doses
• At 40 milligram the half-life was approximately 11 hours, suitable for once-daily dosing
The R&D event includes presentations from leading experts:
• Professor Scott Kopetz, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
• Professor Gisli Jenkins, Faculty of Medicine, National Heart & Lung Institute, Imperial College London
• Professor Toby Maher, Professor of Medicine and Director of Interstitial Lung Disease, Keck School of Medicine, University of Southern California, Los Angeles
To register and receive a link to view the webcast, please email [email protected]. A recording of the webcast will be available on Redx’s website www.redxpharma.com following the event. *Clinicaltrials.gov identifier NCT04931147; data cut-off date 14 September 2021